Physical Exercise Program in Chronic Chagas Heart Disease

Status Completed

Clinical Trial Summary

The aim of this investigation is to evaluate the impact of exercise in a cardiac rehabilitation program on functional capacity, clinical markers, quality of life and biomarkers in patients with chronic chagasic cardiomyopathy.

Clinical Trial Description

The present study consisted in a randomized clinical study conducted at the Evandro Chagas National Institute of Infectious Disease (INI), located on Rio de Janeiro, Brazil. INI is a national reference center for treatment and research in infectious diseases and tropical medicine in Brazil, which follows a large cohort of patients with Chagas disease, all of them diagnosed by two simultaneously positive serological tests (enzyme-linked immunosorbent assay and indirect immunofluorescence). Patients included in the study are randomly divided in two groups: intervention and control groups. Safety analysis will be performed by monitoring any symptoms presented during data collection and follow-up study.

One of the potential risks that the patient may experience during the study is a noninvasive test that will be performed on a treadmill in a controlled environment, with the possibility of the appearance of symptoms such as fatigue, dyspnea, chest pain, dizziness, with minimal chances of occurring complications of difficult clinical control. Except for the blood test and the cardiopulmonary exercise test, the other tests to be performed are non-invasive and do not bring any risk to the participant's health. Will be collect 10 ml of blood which will be stored for up to five years for biomarker assessments.

During the exercise sessions, patients will be clinically monitored for decompensation, need for hospitalization and suspend or end the participation on the study. All cases will be individually assessed to determine the reversibility of the clinical status. Those cases will continue to be followed by the assistant staff, offering all the clinical support available in INI. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02517632
Study type	Interventional
Source	Evandro Chagas National Institute of Infectious Disease
Contact
Status	Completed
Phase	Phase 3
Start date	March 2015
Completion date	January 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01162967` - Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole	Phase 2
Completed	`NCT00023556` - Genetic Architecture of Heart Disease in Rural Brazil	N/A
Active, not recruiting	`NCT04024163` - Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease	Phase 3
Recruiting	`NCT05868005` - Delivering a Multi-disease Screening Tool to Migrant Populations	N/A
Completed	`NCT03892213` - Pharmacokinetic Drug-Drug Interaction Study	Phase 1
Recruiting	`NCT00875173` - Selenium Treatment and Chagasic Cardiopathy (STCC)	Phase 3
Recruiting	`NCT03704181` - Colchicine for Patients With Chagas´ Disease( B1 Stage)	Phase 2
Active, not recruiting	`NCT03378661` - BENDITA BEnznidazole New Doses Improved Treatment and Associations	Phase 2
Completed	`NCT01927224` - Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients	Phase 1
Completed	`NCT01006486` - Outcomes of an Anticoagulation Clinic in an University Hospital	Phase 4
Completed	`NCT00123916` - BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease	Phase 3
Completed	`NCT02516293` - Cardiac Rehabilitation in Chagas Heart Failure	Phase 2/Phase 3
Recruiting	`NCT02099903` - Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease	N/A
Completed	`NCT01874795` - Effect of Ganglionar Electrical Stimulation on Central Arterial Pressure	N/A
Completed	`NCT01006473` - Exercise Training in Chagas Cardiomyopathy	Phase 4
Completed	`NCT02386358` - Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial	Phase 3
Not yet recruiting	`NCT05477953` - An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health
Completed	`NCT02346123` - Determination of Genetic Polymorphisms in Chronic Chagas Cardiomyopathy	N/A
Recruiting	`NCT02295215` - Exercise Training in Patients With Chagasic Heart Disease Without Ventricular Dysfunction	N/A
Completed	`NCT03350295` - Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Physical Exercise Program in Chronic Chagas Heart Disease — PEACH

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms